Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exscientia Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exscientia Plc's position in the market.
Symbotic LLC announced a merger with SVF Investment Corp. 3, valuing the company at approximately
Exscientia (Nasdaq: EXAI) announced that CEO Andrew Hopkins, CFO Ben Taylor, and CTO Garry Pairaudeau will take part in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 10:30 a.m. ET. The chat can be accessed via a live webcast on the company's website, with a replay available for 30 days thereafter. Exscientia, an AI-driven pharmatech firm, has pioneered precision oncology and is advancing over 25 clinical programs, including the first AI-designed drug candidates progressing to Phase 1 trials.
Exscientia (Nasdaq: EXAI) reported significant advancements in its pipeline and collaborations, alongside financial results for Q3 2021. Notably, the company achieved $31.3 million in revenue, a substantial increase from $7.7 million in the same period last year. Key developments include expanded partnerships with Bristol Myers Squibb and the Bill & Melinda Gates Foundation, as well as the integration of Allcyte's tissue platform. Exscientia's cash position at Q3 was $783.7 million, bolstered by a $510.4 million financing. The firm continues to invest in expanding its drug discovery labs and aims for cash inflows of $75.0-$85.0 million for 2021.
Exscientia (Nasdaq: EXAI) will report its third-quarter financial results for the period ending September 30, 2021, on November 17, 2021. The company will host a conference call and webcast on November 18, 2021, at 1:30 p.m. GMT to discuss results and provide insights into its drug development pipeline, which includes more than 25 programs. Exscientia is known for its innovative AI-driven drug discovery processes, having advanced three AI-designed drug candidates into Phase 1 clinical trials.
Exscientia (NASDAQ: EXAI) has announced promising results from the EXALT-1 trial, published in Cancer Discovery. The study demonstrated a 54% clinical benefit in patients with advanced haematological cancers, showing a 1.3-fold increase in progression-free survival (PFS) compared to previous therapies. Additionally, 40% of responders experienced exceptional responses lasting at least three times longer than expected. This data emphasizes the effectiveness of Exscientia's AI-supported precision medicine platform, which tailors therapy based on patient tissue samples, aiming to improve treatment outcomes.
Citi has been appointed as the depositary bank for Exscientia's ADR program, facilitating American Depositary Shares trading on Nasdaq under symbol EXAI. Each ADS represents one ordinary share, enhancing Exscientia's investor outreach. With a commitment to AI-driven drug development, Exscientia has made significant strides, including the advancement of over 25 projects and the launch of three AI-designed drug candidates into Phase 1 clinical trials. This partnership aims to leverage Citi's expertise in investor relations and global equity distribution.
Exscientia plc (NASDAQ: EXAI) has successfully closed its upsized initial public offering of 15,927,500 American Depositary Shares (ADSs) at $22.00 per ADS, raising approximately $350.4 million in gross proceeds. The offering included 2,077,500 ADSs from the full exercise of underwriters' options. Additionally, Exscientia completed a concurrent sale of 7,272,727 ADSs for $160.0 million in gross proceeds, involving private placements to SoftBank and the Bill & Melinda Gates Foundation. The transactions position Exscientia favorably for ongoing drug development.
Exscientia plc (Nasdaq: EXAI) has priced its upsized initial public offering of 13,850,000 American Depositary Shares (ADSs) at $22.00 each, aiming for total gross proceeds of approximately $304.7 million. The ADSs will start trading on Nasdaq on October 1, 2021. Additionally, Exscientia is set to concurrently sell 7,272,727 ADSs for $160 million in private placements to Softbank and the Bill & Melinda Gates Foundation, which will be subject to a 180-day lock-up agreement. The offering is expected to close on or about October 5, 2021.